Johanna Röstin
General Counsel bei VIVESTO AB
Profil
Johanna Röstin currently works at Vivesto AB, as Chief Regulatory Officer.
Ms. Röstin also formerly worked at OxThera AB, as Director-CMC, Program Management & Regulatory and Swedish Orphan Biovitrum AB, as Manager-Global Senior Regulatory Affairs.
Ms. Röstin received her graduate degree from Royal Institute of Technology.
Aktive Positionen von Johanna Röstin
| Unternehmen | Position | Beginn |
|---|---|---|
| VIVESTO AB | General Counsel | 01.10.2021 |
Ehemalige bekannte Positionen von Johanna Röstin
| Unternehmen | Position | Ende |
|---|---|---|
| SWEDISH ORPHAN BIOVITRUM AB | General Counsel | - |
OxThera AB
 OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | General Counsel | - |
Ausbildung von Johanna Röstin
| Royal Institute of Technology | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| VIVESTO AB | Health Technology |
| SWEDISH ORPHAN BIOVITRUM AB | Health Technology |
| Private Unternehmen | 1 |
|---|---|
OxThera AB
OxThera AB Pharmaceuticals: GenericHealth Technology OxThera AB develops pharmaceutical products for treatment of hyperoxaluria. Its intellectual property includes worldwide patents for compositions and treatment of hyperoxaluria with bacteria and enzymes. The firm?s products in pipeline include Oxabact, for the treatment of primary hyperoxaluria and oxazyme for the prevention of oxalate malabsorption and recurring kidney stones in secondary hyperoxaluria. The company was founded in 2005 and is headquartered in Stockholm, Sweden. | Health Technology |
